15 April 2015Americas

PTAB instigates interference on Biogen multiple sclerosis treatment

The US Patent Trial and Appeal Board (PTAB) has instigated an interference proceeding between Biogen and Forward Pharma to determine who first invented a treatment for multiple sclerosis (MS).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
25 March 2021   The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.

More on this story

Big Pharma
25 March 2021   The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.

More on this story

Big Pharma
25 March 2021   The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.